Bringing microbiome-based therapies to patients requires more than promising clinical results. Manufacturing complex mixtures of live bacteria consistently and at commercial scale remains a major challenge. MRM Health is addressing this through its p... Read more
For people living with hereditary angioedema (HAE), sudden and unpredictable swelling attacks can disrupt daily life and require urgent treatment. Pharvaris is developing deucrictibant, an investigational oral therapy designed to provide rapid reli... Read more
For patients living with inflammatory bowel disease (IBD), persistent symptoms, repeated treatment failures and the need for lifelong therapy remain major challenges. InnoCare is developing ICP-B161, a bispecific antibody designed to block two inflam... Read more
For patients living with Fabry disease, progressive kidney damage can lead to dialysis, transplantation and serious long-term complications. Idorsia is developing lucerastat, an investigational oral therapy designed to address the underlying disease ... Read more
ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, announced the successful completion of the second close of its seed financing round, securing an additional €1.6 million, bringing... Read more
Lonza, a global contract development and manufacturing organization, to acquire the CDMO business of Merck Transaction sharpens the focus of Merck’s Life Science business sector and provides the CDMO business with a strong platform for its... Read more
NanoImaging Services, a cryo-EM CRO, and Proteos, a protein production research partner, have announced the launch of TrueCourse Biosciences, an integrated CRO that brings together advanced capabilities to help pharmaceutical and biotechnolog... Read more
As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of therapies must be designed from the outset with potency, manufacturability, scalability, analytical... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
